Geistlich now establishes itself as a strong player in the growing European allograft space through majority ownership of French tissue bank and medical technology company O.S.T Développement. This new majority shareholding represents an expansion of the initial minority investment in 2024. With this step, Geistlich reinforces its long-term commitment to supplying clinicians and experts worldwide with a full range of regenerative products, including high-quality allogeneic bone grafts.
O.S.T Développement has enjoyed an excellent reputation in providing premium-quality allogeneic products for more than 25 years. The OSTEOPURE™ process stands for a very high level of safety as well as a naturally preserved 3D mineralized collagen structure. In dentistry, the allogeneic products are marketed under the brand name Allodyn®. The recent development of Allodyn® with Geistlich as a partner confirms the strategy: demand in France has exceeded initial expectations, and the market entry in the United Kingdom has been very successful. Sandrine Dupriez, Regional Manager Europe, states: “The launch of Allodyn® in France and UK has been a real success story for us, with consistent growth from the start, excellent feedback from dentists, and strong engagement from our sales team, who see it as a meaningful enhancement to our offering.” At the same time, Geistlich distributors in other European countries are in the process of adding Allodyn® to their portfolios and gradually launching it across their markets.
With the majority stake, Geistlich will also gain access to O.S.T's entire orthopedics business – an area that accounts for approximately 70% of O.S.T sales – and will be able to further expand its market presence in orthopedic and Sports Medicine indications such as knee, shoulder, hip and spine surgery in a targeted manner.